Guidance, NICE advice and quality standards In development
Showing 11 to 13 of 13
| Title | Type | Expected publication date |
|---|---|---|
| Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333] | Technology appraisal guidance | |
| Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565 | Technology appraisal guidance | TBC |
| Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040] | Technology appraisal guidance | TBC |